α-Tocopherol decreases interleukin-1β release from activated human monocytes by inhibition of 5-lipoxygenase

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 4, 1999, Pages 1125-1133

  Devaraj, Sridevi ^a,b   Jialal, Ishwarlal ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cytokine; Interleukins; Leukotriene; Protein kinase C; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ARACHIDONATE 5 LIPOXYGENASE; BETA TOCOPHEROL; BISINDOLYLMALEIMIDE; CATALASE; CYTOKINE; INTERLEUKIN 1BETA; LEUKOTRIENE; LEUKOTRIENE B4; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL ADHESION; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; LIPID OXIDATION; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM;

EID: 0032892223     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.4.1125     Document Type: Article

References (70)

1. Gey KF, Puska P, Jordan P, Moser U. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr. 1992;53(suppl):326S-334S.
2. Riemersma R, Wood D, McIntyre C, Elton R, Gey K, Oliver M. Anti-oxidants and pro-oxidants in coronary heart disease. Lancet. 1991;337: 677-679. Letter.
3. Manson JE, Gaziano JM, Jonas MA, Hennekens CH. Antioxidants and cardiovascular disease: a review. J Am Coll Nutr. 1993;12:426-432.
4. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.
5. Rimm EB, Stampfer MJ, Ascherio A, Giovanucci G, Colditz CA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1459.
6. Hodis HN, Mack WJ, La Bree L, Cashin-Hemphill L, Sevanian A, Johnson R, Azen SP. Serial coronary angiographic evidence that anti-oxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA. 1995;273:1849-1854.
7. Jialal I, Fuller CJ, Huet BA. The effect of α-tocopherol supplementation on LDL oxidation: a dose-response study. Arterioscler Thromb Vasc Biol. 1995;15:190-198.
8. Reaven PD, Khou A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans: protection of LDL by vitamin E but not by beta-carotene. Arterioscler Thromb. 1993;13: 590-600.
9. Jialal I, Grundy SM. The effect of combined supplementation with α-tocopherol, ascorbate and beta carotene on low-density lipoprotein oxidation. Circulation2E 1993;88:2780-2786.
10. Devaraj S, Li DJ, Jialal I. The effects of α-tocopherol supplementation on monocyte function: decreased lipid oxidation, interleukin 1β secretion, and monocyte adhesion to endothelium. J Clin Invest. 1996; 98:756-763.
11. Islam KN, Devaraj S, Jialal I. α-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells. Circulation. 1998;98:2255-2261.
12. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
13. Bevilacqua, MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;163:1595-1600.
14. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest. 1985;76:2003-2008.
15. Maziere C, Barbu V, Auclair M, Maziere JC. Interleukin 1 stimulates cholesterol esterification and cholesterol deposition in J774 monocytes-macrophages. Biochim Biophys Acta. 1996;1300:30-34.
16. Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science. 1989; 243:393-395.
17. Lipton BA, Parthasarathy S, Ord VA, Clinton SK, Libby P, Rosenfeld ME. Components of the protein fraction of oxidized low density lipoprotein stimulate interleukin-1α production by rabbit arterial macrophage-derived foam cells. J Lipid Res. 1995;36:2232-2242.
18. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA. 1989;86: 9717-9721.
19. Galea J, Armstrong J, Gadson P, Holden H, Francis SE, Holt CM. Interleukin-1β in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16:1000-1006.
20. Goetzl EJ. Vitamin E modulates the lipoxygenation of arachidonic acid in leukocytes. Nature. 1980;288:183-185.
21. Reddanna P, Rao MK, Reddy CC. Inhibition of 5-lipoxygenase by vitamin E. FEBS Lett. 1985;193:39-43.
22. Reddanna P, Whelan J, Burgess JR, Eskew ML, Hildenbrandt G, Zarkower A, Scholz RW, Reddy C. The role of vitamin E and selenium on arachidonic acid oxidation by way of the 5-lipoxygenase pathway. Ann N Y Acad Sci. 1989;570:136-145.
23. Chan AC, Tran K, Pyke DD, Powell, WS Effects of dietary vitamin E on the biosynthesis of 5-lipoxygenase products by rat polymorphonuclear leukocytes (PMNL). Biochim Biophys Acta. 1989;1005:265-269.
24. Johansson A, Ellis DH, Bates DL, Plumb AM, Stanley CJ. Enzyme amplification for immunoassays: detection limit of one hundredth of an attomole. J Immunol Meth. 1986;87:7-11.
25. Dekker LV, Parker PJ. Protein kinase C-a question of specificity. Trends Biochem Sci. 1994;19:73-77.
26. 4 from human neutrophils and its relationship to degranulation induced by N-formyl-methionyl-leucyl-phenylalanine, serum-treated zymosan and the ionophore A23187. Immunology. 1983;50:65-73.
27. Baxendale PM. Development of scintillation proximity assays for prostaglandins and related compounds. Adv Prostaglandins Leukotriene Res. 1991;21A:303-306.
28. McCord JM, Fridovich I. The utility of superoxide dismutase in studying free radical reactions II: the mechanism of the mediation of cytochrome c reduction by a variety of electron carriers. J Biol Chem. 1970;245: 1374-1377.
29. Fazzio A, Marilley D, Azzi A. The effect of α-tocopherol and β-tocopherol on proliferation, protein kinase C activity and gene expression in different cell lines. Biochem Mol Biol Int. 1997;41:93-101.
30. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
31. Gilman M. Ribonuclcase protection assay. In: Ausubel Frederick M, ed. Current Protocols in Molecular Biology. New York. NY: John Wiley & Sons: 1993;1:471-478.
32. Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC. Dexamethasone inhibition of interleukin 1β production by human monocytes: posttranscriptional mechanisms. J Clin Invest. 1988;81:237-244.
33. Boscoboinik D, Szewczyk A, Hensey C, Azzi A. Inhibition of cell proliferation by α-tocopherol: role of protein kinase C. J Biol Chem. 1991;266:6188-6194.
34. Freedman JE, Farhat JH, Loscalzo J, Keaney JF. α-Tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation. 1996;94:2434-2440.
35. Kasama T, Kobayashi K, Fukushima T, Tabata M, Ohno I, Negishi M, Ide H, Takahashi T, Niwa Y. Production of interleukin 1-like factor from human peripheral blood monocytes and polymorphonuclear leukocytes by superoxide anion: the role of interleukin 1 and reactive oxygen species in inflamed sites. Clin Immunol Immunopathol. 1989; 53:439-448.
36. Burton GW, Ingold KU. Vitamin E as an in vitro and in vivo antioxidant. Ann N Y Acad Sci. 1989;570:7-22.
37. Rola-Plesczczynski M, Lemaire I. Leukotrienes augment interleukin 1 production by human monocytes. J Immunol. 1985;135:3958-3961.
38. 5 on the induction of interleukin 1-like activity and calcium mobilizing activity in human blood monocytes. Agents Actions. 1990;29:324-327.
39. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
40. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet. 1996;347:781-786.
41. Akeson AL, Woods CW, Mosher LB, Thomas CE, Jackson RL. Inhibition of IL-1β expression in THP-1 cells by probucol and tocopherol. Atherosclerosis. 1991;86:261-270.
42. Cannon JG, Meydani SN, Fielding RA, Fiatarone MA, Meydani M, Farhangmehr M, Orencole SF. Acute phase response in exercise II: associations between vitamin E, cytokines, and muscle proteolysis. Am J Physiol. 1991;260:R1235-R1240.
43. Li Q, Cathcart MK. Protein kinase C activity is required for lipid oxidation of low density lipoprotein by activated human monocytes. J Biol Chem. 1994;269:17508-17515.
44. Jialal I, Grundy SM. Effect of dietary supplementation with α-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res. 1992;33:899-906.
45. Reaven PD, Witztum JL. Comparison of supplementation with RRR α-tocopherol and racemic α-tocopherol in humans: effects on lipid levels and lipoprotein susceptibility to oxidation. Arterioscler Thromb. 1993; 13:601-608.
46. Hurme M. Modulation of interleukin-1β production by cyclic AMP in human monocytes. FEBS Lett. 1990;263:35-37.
47. Shapira L, Takashiba S, Champagne C, Amar S, Van Dyke TE. Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-α and IL-1β production by human monocytes. J Immunol. 1994;153:1818-1824.
48. Kamisaki M, Bursell SE, Clermont AC, Ishii H, Ballas LM, Jirousek MR, Umeda F, Nawata H, King GL. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol. 1995;269:E239-E246.
49. Koya D, Lee IK, Ishii H, Kanoh H, King GL. Prevention of glomerular dysfunction in diabetic rats by treatment of D-α-tocophorel. J Am Soc Nephrol. 1997;8:426-435.
50. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991;266:15771-15781.
51. Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med. 1992;116:1292-1300.
52. Stauble B, Boscoboinik D, Tasinato A, Azzi A. Modulation of activator protein-1 (AP-1 ) transcription factor and protein kinase C by hydrogen peroxide and D-α-tocopherol in vascular smooth muscle cells. Eur J Biochem. 1994;226:393-402.
53. Williams JD, Czop JK, Austen KF. Release of leukotrienes by human monocytes on stimulation of their phagocyte receptor for particulate activators. J Immunol. 1984;132:3034-3040.
54. Chensue SW, Kunkel SL. Induction of IL-1 release by leukotrienes. Fed Proc. 1985;44:1270.
55. Dinarello CA, Bishai I, Rosenwasser LJ, Coceani F. The influence of lipoxygenase inhibitors on the in vitro production of human leukocytic pyrogen and lymphocyte activating factor (interleukin-1). Int J Immunopharmacol. 1984;6:43-50.
56. Rouzer CA, Ford-Hutchinson AW, Morton HE, Gillard GW. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem. 1990;265:1436-1442.
57. Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H, et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2- dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1989;67:456-464.
58. Ford-Hutchinson AW, Gresser M, Young RN. 5-Lipoxygenase. Annu Rev Biochem. 1994;63:383-417.
59. Folcik VA, Cathcart MK. Assessment of 5-lipoxygenase involvement in human monocyte-mediated LDL oxidation. J Lipid Res. 1993;34:69-79.
60. Gagnon I, Filion G, Duhois C, Rola Pleszczynski M. Leukotrienes and macrophage activation: augmented cytotoxic activity and enhanced interleukin 1, tumor necrosis factor and hydrogen peroxide production. Agents Actions. 1989;26:141-147.
61. Rainsford KD, Ying C, Smith F. Selective effects of some 5-lipoxygenase inhibitors on synovial interleukin-1 (IL-1) production compared with IL-1 synthesis inhibitors. Agents Actions. 1993;39:C186-C188.
62. Hoffman T, Lee YL, Lizzio EF, Tripathi AK, Jessop JJ, Taplits M, Abrahamsen TG, Carter CS, Puri J. Absence of modulation of monokine production via endogenous cyclooxygenase or 5-lipoxygenase metabolites. Clin Immunol Immunopathol. 1991;58:399-408.
63. Kunkel SL, Chensue SW, Phan SH. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol. 1986;136:186-192.
64. Knudsen PJ, Dinarello CA, Strom TB. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by decreasing intracellular cyclic adenosine monophosphate. J Immunol. 1986;137:3189-3194.
65. 2 and superoxide production in rat peritoneal macrophages. Biochim Biophys Acta. 1991;1074:251-255.
66. Romach EH, Kidao S, Sanders BG, Kline K. Effects of RRR-α-tocopherol succinate on IL-1 and PGE, production by macrophages. Nutr Cancer. 1993;20:205-214.
67. Kassis S, Lee JC, Hanna N. Effects of prostaglandins and cAMP levels on monocyte IL-1 production. Agents Actions. 1989;27:274-276.
68. 2. J Biol Chem. 1997;272:25693-25699.
69. 2 in nonadherent human monocytes. J Immunol. 1997;158:351-358.
70. Devaraj S, Jialal I. The effects of α-tocopherol on critical cells in atherogenesis. Curr Opin Lipidol. 1998;9:11-15.